Objective-Clinical studies have identified that reduced numbers of circulating plasmacytoid dendritic cells (pDCs) act as a predictor of cardiovascular events in coronary artery disease and that pDCs are detectable in the shoulder region of human atherosclerotic plaques, where rupture is most likely to occur. Results from animal models are controversial, with pDCs seen to inhibit or promote lesion development depending on the experimental settings. Here, we investigated the role of pDCs in atherosclerosis in apolipoprotein E−deficient mice. Methods and Results-We demonstrated that the aorta and spleen of both apolipoprotein E−deficient and C57BL/6 mice displayed similar numbers of pDCs, with similar activation status. In contrast, assessment of antigen uptake/presentation using the Eα/Y-Ae system revealed that aortic pDCs in apolipoprotein E−deficientmice were capable of presenting in vivo systemically administered antigen. Continuous treatment of apolipoprotein E−deficient mice with anti−mouse plasmacytoid dendritic cell antigen 1 (mPDCA-1) antibody caused specific depletion of pDCs in the aorta and spleen and significantly reduced atherosclerosis formation in the aortic sinus (by 46%; P<0.001). Depletion of pDCs also reduced macrophages (by 34%; P<0.05) and increased collagen content (by 41%; P<0.05) in aortic plaques, implying a more stable plaque phenotype. Additionally, pDC depletion reduced splenic T-cell activation and inhibited interleukin-12, chemokine (C-X-C motif) ligand 1, monokine induced by interferon-γ, interferon γ−induced protein 10, and vascular endothelium growth factor serum levels. Conclusion-These results identify a critical role for pDCs in atherosclerosis and suggest a potential role for pDC targeting in the control of the pathology. (Arterioscler Thromb Vasc Biol. 2012;32:2569-2579.)
I mmune−inflammatory responses play a key role in atherosclerosis, and consequently current research is now focused on understanding what drives this inflammation and how it is regulated. Multiple leukocyte subsets accumulate within the atherosclerotic arterial wall contributing to progression of the disease. [1] [2] [3] Among them, dendritic cells, potent antigen presenting cells (APCs), have been associated with atherosclerosis development. 2 Dendritic cells can be classified into 2 distinct lineages: conventional dendritic cells (cDCs) and plasmacytoid dendritic cells (pDCs). The effective contribution of pDCs to atherosclerosis is still controversial despite several observations suggesting their involvement in the pathology.
pDCs are plasma like cells, initially known as T-cell− associated plasma cells and natural interferon producing cells. Murine pDCs are characterized by the expression of B220, 4 Ly6C, bone marrow stromal cell antigen 2 (BST-2), 5 lymphocyte activation marker-3, 6 C-C chemokine receptor type 9 (CCR9), 7 siglec-H, 8 in addition to low levels of CD11c. The canonical function of pDCs is to secrete type 1 interferons, such as interferon (IFN)-α, 9 that have potent antiviral activity, 10 such as expansion of CD8 cytotoxic T cells 11 and the induction of a T helper 1 polarized CD4−mediated response 12 associated with atherosclerosis development and complications. 2 After stimulation, pDCs acquire dendritic-like morphology and upregulate major histocompatibility complex (MHC) Class II and T-cell costimulatory molecules, and there is mounting evidence that pDCs can indeed function as APCs 13 in vivo with both immunogenic 11, 14, 15 and tolerogenic [16] [17] [18] [19] functions being described.
Recent observations have suggested a potential role for pDCs in cardiovascular diseases. 20, 21 The number of circulating pDCs have been shown to decrease in coronary artery disease, [22] [23] [24] whereas a study of stable coronary artery disease patients found a stage-dependent decrease in the number of circulating pDC precursors that could act as an independent predictor of pathology and the requirement for percutaneous coronary intervention or coronary artery bypass grafting. 25 pDCs are present in human atherosclerotic lesions [26] [27] [28] preferentially located in the plaque shoulder region. 26 Results from animal models are controversial. Recently, pDCs have been shown to protect against atherosclerosis by tuning T-cell proliferation/activity in an atherosclerotic lesion−induced model (semiconstrictive collar placement) in low-density lipoprotein receptor (LDLr) −/− mice. 27 On the contrary, autoantigenic protein−DNA complexes stimulated pDCs to promote atherosclerosis in apolipoprotein E−deficient (apoE −/− ) mice. 28 More studies are needed to address the functional contribution of pDCs to pathogenesis and disease.
Our data demonstrate the presence of similar numbers of pDCs, with a similar activation phenotype, in the spleen and aorta of both apoE −/− and wild-type (WT) mice. Aortic pDCs from apoE −/− , but not WT, mice were able to act as APCs in vivo. Importantly, continuous pDC depletion reduced atherosclerosis formation in the aortic sinus leading to a more stable plaque phenotype, decreased systemic immune cell activation, and circulating proinflammatory/atherosclerotic mediators. The results provided in this study support a critical role for pDCs in driving early atherosclerosis formation and suggest novel therapeutic strategies to target this cell population for vascular therapy.
Materials and Methods

Animals
B6.129P2-Apoe(tm1Unc)/J (apoE −/− ) mice (12-16 weeks of age; 6 months old for the Eα experiments) were bred in-house (Central Research Facility, University of Glasgow) or purchased from Charles River (Margate, UK). Age-matched C57BL/6 mice (Harlan, Shardlow, UK) were used as controls. OT-II (CD45.1) and OT-II (CD45.2) mice bred in-house were used as donors of transgenic T cells and for aortic T-cell proliferation studies, respectively. These transgenic mice express the mouse α-chain and β-chain T-cell receptor that pairs with the CD4 coreceptor and is specific for chicken ovalbumin 323 to 339 in the context of I-A b. Animals were maintained on a 12/12-hour light/dark cycle with free access to food and water, and all the procedures were performed in accordance with local ethical and UK Home Office regulations.
Administration of Eα-Green Fluoroscent Protein
To assess the ability of pDCs to uptake and present systemic antigen, we used the Eα-GFP/Y-Ae system, which can identify antigen presentation in vivo 29 through the ability of the Y-Ae antibody to recognize the Eα peptide in the context of MHC (I-A b ). ApoE −/− or C57BL/6 mice received either 1 mg of Eα-GFP or PBS IV and were culled 1, 4, 24, and 72 hours later for flow cytometric analysis.
Flow Cytometry
Flow cytometry of the aorta was performed according to Galkina et al 30 with minor modifications. Briefly, C57BL/6 and apoE −/− mice were placed under terminal anesthesia and perfused with 2 mmol/L EDTA (Sigma-Aldrich, Gillingham, UK) in PBS via cardiac puncture to remove blood contamination from vascular tissue. After removal of aortas, a single cell suspension was obtained by incubation of aortic segments in an enzymatic suspension containing 450 U/mL collagenase type I, 125 U/mL collagenase type XI, 60 U/ mL hyaluronidase, and 60 U/mL DNase (all from Sigma-Aldrich) in PBS containing 20 mmol/L Hepes at 37°C for 1 hour. Digested aortas plus spleen or lymph nodes were then mechanically disrupted through a 40-µmol/L cell strainer to release a single cell suspension. Aliquots of cells were washed and resuspended in Fc block (2.4G2 hybridoma supernatant) for 25 minutes at 4°C to block Fc receptors. Subsequently, cells were incubated with Abs (in PBS containing 2% FCS) for 30 minutes at 4°C, washed twice, and then, where necessary, incubated with secondary Abs for an additional 20 minutes at 4°C. After washing, cells were analyzed on a FACS calibur using CellQuest pro (BD Biosciences, Oxford, UK) or MACSQuant Analyzer (Miltenyi Biotec, Bisley, UK), and data analysis was performed using FlowJo (Tree Star Inc, Olten, Switzerland). Abs used were Y-Ae-bio (specific for Eα 52-68 presented on I-A b ; ebioY-Ae), CD4-APC (GK1.5), CD8a-V450 (53-6.7), CD69-PE-Cy7 (H1.2F3), CD11b-PE-Cy7 (M1/70), CD40-PE (3/23), CCR9-PE (ebioCW-1.2) from eBioscience (Hatfield, UK), PDCA-1-APC (JF05-1C2.4.1) from Miltenyi Biotec, Vα2 TCR-APC (B20.1) from Invitrogen (Paisley, UK), CD45-PerCP (30-F11), CD11c-FITC (HL3), CD11cbio (HL3), B220-PE (RA3-6132), CD86-FITC (GL1), CD3e-bio (145-2C11), CD45.1-bio (A20), CD62L-FITC (MEL-14), CD44-PE (IM7) I-A/I-E-FITC (2G9), Vβ 5.1, 5.2 TCR (MR9-4), appropriate isotype controls, streptavidin-PE, and streptavidin-APC-Cy7 from BD Biosciences.
All the Abs used for flow cytometry analysis of mouse aorta had been validated on cell suspensions from spleen/lymph nodes untreated or treated with the enzyme digestion cocktail.
Depletion of pDCs In Vivo
Twelve-week-old female apoE −/− mice were fed a high-fat diet (HFD; Code 821424, Special Diets Services, Essex, United Kingdom) for 28 days. pDCs were depleted in vivo by an IP injection of 250 µg of anti-mouse plasmacytoid dendritic cell antigen-1 (anti−mPDCA-1) Ab (JF05-1C2.4.1, rat IgG2b; Miltenyi Biotec) administered starting from day 0 every fifth day. Control mice received an injection of 250 µg of the isotype control Ab (Rat IgG2b; Bio X Cell, NH). Mice were culled at 28 days (3 days after the final Ab injection) and samples processed as described below. To assess efficacy and specificity of pDC depletion, 12-week-old apoE −/− mice received an IP injection of 250 µg anti−mPDCA-1 and were culled 24 hours, 72 hours, or 5 days later. pDC (CD11c low B220+PDCA-1+), conventional dendritic cells (CD11c high ), B-cell (B220+), T-cell (CD3e+), and CD11b high populations were assessed by flow cytometry on single cell suspensions from spleen, lymph nodes (inguinal, brachial, axillary, and cervical), blood, and aorta.
Morphometric Analysis
At the end of the experimental protocol mice were perfused with ice cold PBS; the heart was embedded in Tissue-Tec OCT (Tissue Tek, Sakura Finetek Europe, Zoeterwoude, The Netherlands), frozen at −80°C, and sectioned (10 µm). Aortic sinus sections were stained with oil red O counterstained with hematoxylin. Picrosirius red viewed with polarized light was used to detect collagen. For each animal, 10 sections were analyzed, under blinded conditions, to determine atherosclerotic lesion size and collagen content. The analyses were carried out using Image J software (National Institutes of Health Imaging; http://rsbweb.nih.gov/ij), and the results are expressed as mean lesion area and mean percentage collagen area, respectively.
Immunohistochemical Analysis
Sinus sections were used for CD68 and α-smooth muscle actin detection by immunofluorescence. For staining, sections were fixed in acetone for 10 minutes, air dried, and rehydrated with PBS before incubation in serum-free Protein Block (DakoCytomation, Milan, Italy) for 30 minutes. To detect CD68, sections were stained with rat anti-mouse CD68 antibody (1:500; AbSerotec, Oxford, UK) diluted in 1% blocking reagent (Perkin Elmer, Cambridge, UK) and 0.3% Triton X-100 in PBS overnight before being washed in TNT wash buffer (Tris-HCl; pH 7.5; 0.15 mol/L NaCl; and 0.05% Tween 20, Sigma-Aldrich). Sections incubated with an isotype-matched control antibody were used as negative control. Subsequently, sections were incubated with 1/200 Texas Red-donkey anti-rat IgG (Jackson ImmunoResearch Laboratories, Soham, UK) for 30 minutes before washing. Monoclonal anti-α-smooth muscle actin fluorescein isothiocyanate conjugate (1/100, clone 1A4, Sigma-Aldrich) was added in blocking buffer for 1 hour before washing as described above. Dapi was used to identify nuclei. pDCs were detected by staining for Siglec-H (440c, HyCult Biotech, Uden, The Netherlands) in the aortic root of 12-week-old female apoE −/− mice (n=5) fed a HFD for 28 days. Five fixed frozen sections from each animal were analyzed. The primary antibody was detected using a Texas Red conjugated donkey anti-rat IgG (Jackson ImmunoResearch). Images were taken by a Leica DFC340 FX video-camera (Leica Microsystems, Milan, Italy) connected to a fluorescence microscope (Leica DMRB) using the LAS software (version 2.8.1, Leica).
All immunohistochemical analyses were carried out using Image J software. Ten sections from each mouse were reviewed and scored under blinded conditions. The percentage of α-smooth muscle actinpositive cells was determined by counting all nucleated cells with or without fluorescein isothiocyanate fluorescence in the plaque. The results are expressed as positive on total cell ratio. Plaque macrophage content was determined by color thresholds and represented as percentage area of CD68 immunostaining.
In Vitro Stimulation of Mouse Splenic T Lymphocytes
Spleens were removed and mechanically disrupted through a 40-µmol/L cell strainer to release a single cell suspension. Red blood cells were removed using red blood cells lysis buffer (eBioscience), and cells were cultured in round-bottom, 96-well plates (2×10 5 cells/ well) containing RPMI 1640 media supplemented with 10% heatinactivated fetal calf serum (FCS), 2 mmol/L L-glutamine, 100 U/mL penicillin, and 100 µg/Ll streptomycin. Cells were stimulated with 1 µg/mL purified soluble CD3-specific antibody (BD Biosciences). Supernatants were collected at 48 hours for cytokine detection.
Cytokine Detection Assays
Concentrations of fibroblast growth factor-basic, granulocyte-macrophage colony-stimulating factor, IFN-γ, interleukin (IL)-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17, IFN γ−induced protein 10, KC (chemokine [C-X-C motif] ligand [CXCL] 1), monocyte chemoattractant protein-1, monokine induced by IFN-γ, macrophage inflammatory protein-1α, tumor necrosis factor-α (TNF-α), and vascular endothelium growth factor were assessed in serum and splenocyte culture supernatant using a 20-plex mouse cytokine assay according to the manufacturer's instructions (Invitrogen) and analyzed using a Bio-Rad Luminex 100 Plate Reader (Hemel Hempstead, United Kingdom).
IFN-α levels in serum and aortic protein extracts were analyzed by an ELISA kit (PBL Biomedical Laboratories, Piscataway, NJ). Briefly, mouse aorta was crushed into powder and resuspended in 100 mL of lysis buffer (20 mmol/L HEPES, 0.4 mmol/L NaCl, 1.5 mmol/l MgCl2, 1 mmol/L EGTA, 1 mmol/l EDTA, 1% Triton X-100, and 20% glycerol) with protease inhibitors (1 mmol/L 1,4-Dithiothreitol, 0.5 mmol/L phenylmethylsulfonyl fluoride, 15 mg/mL Try-inhibitor, 3 mg/mL pepstatin-A, 2 mg/mL leupeptin, and 40 mmol/L benzamidine). After centrifugation at 13 000g at 4°C for 30 minutes, IFN-α in the supernatant was quantified by ELISA. Samples from supernatant and serum were run in duplicate and analyzed at an absorbance of 450 nm according to the manufacturer's instructions. The threshold of detection was 12.5 pg/mL. The values were corrected by protein concentrations measured by NanoDrop (Thermo Scientific, Wilmington, DE).
In Vivo T-Cell Proliferation Assay
Spleens and peripheral lymph nodes were removed from OT-II (CD45.1) donor mice and mechanically disrupted through a 40 µmol/L cell strainer to release a single cell suspension. Red blood cells were removed using red blood cell's lysis buffer. CD4+ T cells were then isolated via negative selection using a CD4+ T cell Isolation Kit (Miltenyi Biotec) according to the manufacturer's instructions. CD4+ T cells were washed twice in Hank's Balanced Salt Solution and resuspended at a concentration of 5×10 7 cells/mL and stained with 5 µmol/L 5(6)-CFDA, SE (5-(and-6)-Carboxyfluorescein diacetate, succinimidyl ester) (CFSE), (Molecular Probes, Invitrogen). Cells were resuspended at a concentration of 1×10 7 cells/mL in PBS and the apoE −/− (CD45.2) recipient mice received 2×10 6 CFSE-labeled OT-II CD4+/CD45.1 T cells via IV injection concurrent with 250 µg of anti-PDCA-1 or rat IgG2b isotype administered via IP injection (day 0). 24 hours later (day 1), the mice received 200 µg of ovalbumin IV. The next day (day 2), mice received an additional IP injection of 250 µg of anti-PDCA-1 or Rat IgG2b isotype to ensure complete depletion of pDCs for the duration of the experiment. Mice were culled 48 hours later (day 4), and spleen, aorta, and para-aortic lymph nodes were processed for flow cytometry analysis of OT-II CD4+/CD45.1 T-cell proliferation based on CFSE dilution. For 5-Bromo-2′-deoxyuridine (BrdU) proliferation assay, OT-II (CD45.2) mice were administered 250 µg anti-mPDCA-1 or isotype. Twelve hours later, mice received IV injection of 200 µg ovalbumin. The following day, each mouse received 1 mg of BrdU (Sigma-Aldrich) via IP injection 2 hours before euthanization (24 hours after ovalbumin administration). BrdU intracellular staining was performed using an FITC BrdU flow kit (from Becton Dickinson, Oxford, United Kingdom) according to the manufacturer's instructions.
Lipid Profile
Total serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels were measured by enzymatic assay on a clinically validated automated platform using the manufacturer's calibrators and quality control material (c311, Roche Diagnostics, Burgess Hill, United Kingdom). Elevated triglyceride concentrations in the present models precluded indirect calculation of low-density lipoprotein (LDL) by the Friedewald equation.
Statistical Analysis
Results are expressed as mean±SEM of n animals for in vivo experiments. Student t test was used to compare 2 groups, and ANOVA (1 or 2-way) was used with the Bonferroni post hoc test using Graph Pad Instat 3 software (San Diego, CA). A P value <0.05 was taken to indicate statistical significance.
Results pDCs Are Constitutively Present in Aortic Tissue
pDCs are present in the human and murine atherosclerotic arteries [26] [27] [28] but evidence is lacking for their presence in normal, noninflamed arteries. 31 We used flow cytometry to examine the entire aortic vessel for the presence of pDCs in C57BL/6 mice ( Figure 1A) . pDCs constituted ≈0.2% of the total CD45+ leukocyte population. To determine whether pDC number was altered in atherosclerosis, we next examined aortic segments from age-matched apoE −/− mice. The proportion of pDCs within the leukocyte population was similar to that observed in WT mice. Quantification of conventional dendritic cells (CD11c high cells) revealed a similar intragroup distribution of values to pDCs with no signification differences between groups. B-cell number was also equivalent between groups (Figure I in the online-only Data Supplement). Similar numbers of splenic pDCs were observed between the two groups ( Figure 1B ).
Assessment of Aortic, Lymphoid, and Splenic pDC Phenotype in ApoE −/− and C57BL/6 Mice
We next characterized pDC phenotype. Figure 2 displays the percentage of aortic (A), lymphoid (B), and splenic (C) pDCs that expressed the classic dendritic cell activation markers: CD40 and CD86, MHC-II, and CCR9, a chemokine receptor expressed on immature pDCs but which is downregulated after maturation. 32 CD40 and CD86 were detectable on a minority of aortic pDCs from both C57BL/6 and apoE −/− mice, indicating that the majority of aortic pDCs are in an immature state. Although a trend toward increased CD86 was observed in apoE −/− mice, this did not reach significance. The frequency of MHC-II high and CCR9+ pDCs did not significantly differ between groups. Lymphoid and splenic pDCs from apoE −/− and C57BL/6 mice had similar levels of CD40+, CD86+, and MHC-II high pDCs. CCR9, however, was significantly reduced on lymphoid pDCs from apoE −/− mice.
Aortic pDCs From ApoE −/− Mice Can Function as APCs In Vivo
Recently, exposure to oxidized LDL has been show to enhance the capacity of pDCs to phagocytose and prime antigen− specific T-cell responses; 28 however, it is not known whether vascular pDCs can function as APCs in vivo or whether antigen presenting capacity is affected in the context of atherosclerosis. In this investigation, we used the model antigen Eα-GFP together with the Y-Ae monoclonal Ab to determine whether aortic pDCs could acquire, process, and present systemically administered antigens in vivo ( Figure 2D−2F) . A significant increase (P<0.01) in antigen uptake (GFP+ cells) was observed in the aortic pDCs from apoE −/− mice 1 hour after Eα-GFP administration ( Figure 2D ). A significant increase in Y-Ae expression was observed on aortic pDCs from apoE −/− mice at 1 (P<0.01) and 4 hours (P<0.001) after Eα-GFP administration, whereas less presentation was apparent in similarly treated C57BL/6 controls ( Figure 2E ). Mean fluorescence intensity data showed no difference between WT and apoE −/− mice (data not shown). Antigen presentation peaked, although not reaching statistical significance, at 1 hour in the control tissue spleen with no difference observed between apoE −/− and WT mice ( Figure 2F ). GFP was not detectable in spleen at any of the time points analyzed. These data are consistent with the rapid antigen uptake and processing by spleen cells, which has been observed as early as 10 to 15 minutes after intravenous antigen administration. 33
Administration of Anti−mPDCA-1 Significantly and Selectively Depletes pDCs In Vivo
To directly investigate the role of pDCs in the pathology of atherosclerosis, apoE −/− mice were subjected to 28 days HFD to accelerate lesion development. During the course of the HFD, pDCs were depleted using the anti-mPDCA-1 monoclonal antibody, which targets bone marrow stromal cell antigen 2, a transmembrane protein, specifically expressed on pDCs in the naïve mouse. 5 To determine the efficacy and kinetics of pDC depletion using anti−mPDCA-1, apoE −/− mice were injected with 250 µg anti-mPDCA-1 and culled at 24 hours, 72 hours, or 5 days after injection (Figure 3 ). pDCs were significantly depleted in spleen, lymph nodes, blood (P<0.05), and aorta (P<0.01) at 24 hours with maximum depletion observed in spleen (≈95%). Depletion was also evident at 72 hours in spleen, lymph nodes (P<0.05), and blood (P<0.01). Interestingly, whereas lymphoid, aortic, and blood pDCs had returned to near control levels by day 5, the splenic pDC population was still <50% recovered. No significant differences were observed for other leukocyte populations at any time point ( Figure II in the online-only Data Supplement). Collectively these data indicate that anti-mPDCA-1 induces a specific and systemic depletion of pDCs. [34] [35] [36] [37] To continuously deplete pDCs and to limit the amount of (rat) antibody administered to the mice, and hence the probability of a serum response, we settled the frequency of dosing to every 5 days.
Depletion of pDCs Reduces Experimental Atherosclerosis
Depletion of pDCs significantly decreased (by 46%, P<0.001) aortic sinus plaque formation compared with the isotype control group ( Figure 4A) . Concomitantly, anti-mPDCA-1 treatment significantly increased plaque collagen content (by 41%; P<0.05; Figure 4B ), slightly increased, although not reaching significance, plaque content of α-smooth muscle actin-positive cells ( Figure 4C) , and significantly decreased macrophage lesion content (by 34%, P<0.05; Figure 4D ). IFN-α levels were below detection limits in the aortic protein extracts and in serum samples from both the analyzed groups. The decreased macrophage content coupled with an increase in collagen fibers observed in aortic sinus lesions after pDC depletion is consistent with a more stable plaque phenotype. Siglec-H+ pDCs located at the plaque shoulder in most of the aortic sinuses from apoE −/− mice fed HFD. In few sections, pDCs were detectable also in close proximity to the necrotic core ( Figure III in the online-only Data Supplement).
No significant differences in cholesterol and triglyceride levels were noted between groups ( Figure IV in the onlineonly Data Supplement). It is therefore unlikely that changes in lipid levels account for the decreased pathology observed in pDC-depleted mice. Data for chow diet-fed apoE −/− mice are also shown to confirm the efficacy of the HFD in raising serum lipid levels.
pDC Depletion Reduces Splenic T-Cell Activation
T-cell activation is necessary for progression of atherosclerotic lesions in apoE −/− mice, 38 and pDCs can induce T-cell activation and proliferation. 34 Therefore, we characterized the phenotype of both CD4+ and CD8+ T cells in the spleen of pDC-depleted mice after HFD ( Figure 5A-5C ). Although overall numbers of T cells were similar between groups, we observed a decrease (P<0.05) in the frequency of CD69+ T cells (both CD4+ and CD8+) in the spleens of pDC-depleted mice ( Figure 5A and 5B, respectively). Moreover, a greater proportion of CD8+ T cells in control mice were CD44+ (P<0.05; Figure 5C ).
pDC Depletion Does Not Affect Splenic Antigen-Specific CD4+ T-Cell Proliferation
Having demonstrated that pDCs can acquire and present systemic antigen and that pDC depletion reduces splenic T-cell activation in apoE −/− mice on HFD, our next step was to assess the contribution of pDCs in antigen-dependent proliferation of CD4+ T cells. Adoptively transferred OT-II (CD45.1) CD4+ T cells proliferated in both spleen and para-aortic lymph nodes after administration of ovalbumin ( Figure 5D and 5E). Depletion of pDCs did not affect the proliferation of the transferred population indicating other antigen presenting cell populations are inducing systemic T-cell proliferation. Proliferation of OT-II CD4+ T cells could not be accurately quantified in aortic tissue because of the scarcity of transferred cells in this tissue (data not shown). To evaluate the effect of 
pDC Depletion Results in Systemic Reductions in Proatherosclerotic Mediators
To determine wider systemic changes that pDC depletion may exert on atherosclerotic immune responses, we performed luminex analysis to quantify a broad spectrum of cytokines in the serum samples derived from our pDC-depleted and control mice ( Figure 6A ). We observed a >90% (P<0.05) decrease in IL-12, a proatherogenic cytokine in pDC-depleted mice in addition to decreases in the proatherogenic chemokines: KC (chemokine [C-X-C motif] ligand [CXCL] 1), monokine induced by IFN-γ/CXCL9, and IFN-γ−induced protein 10/CXCL10. Vascular endothelium growth factor, the concentration of which increases in both serum and plaques during atherosclerosis, 39, 40 was found to be reduced by 75% (P<0.05) in pDC-depleted mice. Concentrations of fibroblast growth factor-basic, granulocyte-macrophage colony-stimulating factor, IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-13, IL-17, monocyte chemoattractant protein-1, macrophage inflammatory protein-1α, and TNF-α did not differ significantly between groups or were below the level of detection (data not shown). The anti-inflammatory effect of pDC depletion was confirmed in supernatants of splenic T cells cultured in vitro with anti-CD3 antibody ( Figure  6B ). Cells from pDC-depleted mice produced signficantly (P<0.05) less TNF-α compared with controls. Surprisingly, levels of IL-6 were elevated (P<0.01) in pDC-depleted mice. Concentrations of the other molecules analyzed did not differ significantly between groups or were below the level of detection (data not shown).
Discussion
The present results identify a critical role for pDCs in experimental atherosclerosis suggesting new potential anti-atherogenic strategies based on pDC targeting. In this study, we have established that pDCs are constitutively present within the aorta and that antigen presentation, a key feature in the initiation of atherosclerotic adaptive immune response, 41, 42 is increased in aortic pDCs from apoE −/− mice compared with WT controls. Most importantly, we demonstrated that pDC depletion reduced systemic immune-inflammatory response, atherosclerosis formation, lesion macrophage content, and increased plaque collagen deposition, implying a more stable plaque phenotype. 43 We have been able to show that pDCs reside in the aorta of both apoE −/− and WT mice. We found no significant differences between the 2 groups. These results are in contrast with the increased recruitment of pDCs observed in human atherosclerotic plaques. 26 This notion was largely based on the fact that plaques were shown to express CD123+ cells, in particular when progressed to an unstable phenotype. However, CD123 staining has shown not to be entirely reflective of the pDC content of the plaque because macrophages and smooth muscle cells appear to express this marker. 27 More recently, the actual plaque pDC content has been shown to be lower than originally envisioned and that it does not markedly increase with progression of disease. 27 Moreover, pDC total number in the spleen was comparable between apoE −/− and C57BL/6 mice with pDCs accounting for 0.1% of the total leukocyte population. We next showed a similar activation phenotype of aortic, lymphoid, and splenic pDCs in apoE −/− mice compared with controls. These data are somewhat surprising; however, similar results were recently obtained in vitro. 28 Oxidized LDL, in fact, enhanced phagocytosis of sorted pDCs and their capacity to prime antigen−specific T-cell responses, while not altering surface expression of MHC-II and CD86, nor secretion of IFN-αβ. 28 Intriguingly, in recent years, evidence has emerged that pDCs can function as APCs. 13, 15, 17 We were, therefore, interested to ascertain whether aortic pDCs could function as APCs in vivo. We demonstrate that aortic pDCs from apoE −/− mice are able to uptake and present antigen in the context of MHC-II. In contrast, aortic pDCs from WT mice were less capable of presenting systemically administered antigen. Our results highlight an important functional difference in pDCs between mice with and without atherosclerosis. Indeed, our results are the first direct demonstration of antigen presentation in vivo in the mouse aorta and outline the importance of the local atherosclerotic immune response in the inflamed vessel. Because of technical limitations, we have not been able to demonstrate the direct effect of this increased antigen presentation on aortic Ag-specific T-cell proliferation. However, it should be mentioned that recently sorted pDCs have been shown capable of taking up di-labeled oxidized LDL or fluorescent-labeled ovalbumin in vitro. 28 Exposure to oxidized LDL selectively enhanced the surface expression of the scavenger receptor CD36, enhanced phagocytic capacity of pDCs and their capacity to prime antigen-specific T-cell responses. 28 Intriguingly, pDC depletion significantly affected Ag-specific T-cell proliferation in the aorta of OT-II Tg mice. Obviously, data obtained using a reductionist system in healthy Tg mice aortas cannot be extrapolated to atherosclerotic vessels where chronic inflammation, increased costimulation, and enhanced phagocytic capacity of pDCs could induce these cells to prime antigen-specific T-cell responses. All together these data support the hypothesis that pDCs could play a key role as APCs in the atherosclerotic vessel where pDCs may be exposed to several disease related antigens, including viral antigens 44 and modified self-nucleic acid complexes that may be released from dying cells. 10 Of relevance is the fact that pDCs have been recently shown to specifically promote double-stranded DNA-Ab formation in early atherosclerosis. 28 Importantly, we demonstrated that pDC depletion significantly reduced atherosclerosis formation in the aortic sinus, leading to a more stable plaque phenotype by reducing lesion macrophage content and increasing collagen deposition in the plaque. Recent publications have shown contrasting results. Beissen et al 27 have shown that pDCS protect against atherosclerosis by tuning T-cell proliferation/activity in a vascular injury induced model (semiconstrictive collar placement) in low-density lipoprotein receptor −/− mice. On the contrary, Zernecke et al 28 demonstrated a proatherogenic role for pDCs in apoE −/− mice. These authors also used an Ab depletion approach performed by iv. injection of the monoclonal antibody PDCA-1 only on day 1 and 7 during 32 days of HFD. Considering the Ab kinetic and continuous depletion efficiency it means that they have only partially depleted pDCs throughout the feeding experiment. Thus, the results from our continuous depletion study support a key role for pDCs in promoting early lesion formation in apoE −/− mice.
Interestingly, pDC depletion also induced a robust systemic anti-inflammatory effect. T-cell activation was decreased in the spleen of depleted mice compared with controls. Splenic T cells from pDC-depleted mice produced significantly less TNF-α, a cytokine know to play a key role in vascular pathology. 45 The concentration of IL-6 was elevated in the supernatant of splenic cells from pDC-depleted mice compared with controls. IL-6, from one side, represents an independent risk factor for coronary artery disease in humans and is crucially involved in vascular inflammatory processes, 46 but it may also be regarded as an anti-inflammatory cytokine as it induces the synthesis of IL-1 receptor antagonist, release of soluble TNF receptor, 47 and it may also inhibit macrophage scavenger receptor-A. 48 By contrast, pDC depletion did not affect the proliferation of transferred Ag-specific Tg CD4+ T cells in the spleen. These data are in agreement with the minor role played by these cellular subset as APCs in the spleen. Contrasting results were obtained in a vascular injury model in low-density lipoprotein receptor −/− mice, 27 were pDC depletion has been shown to increase splenic CD4+ T-cell proliferation and activity. The different animal model used as such as the different dose regimen used for pDC depletion could explain these contrasting data.
Importantly, pDC depletion induced a systemic reduction of proatherosclerotic circulating mediators, such as IL-12, which is produced by dendritic cells and monocytes/macrophages and plays a critical role in T helper 1 polarization, 45 CXCL1, 49, 50 monokine induced by IFN-γ/CXCL9, and-γ− induced protein 10/CXCL10 that are IFN-γ-induced chemokines, which play important roles in the vascular recruitment of immune cells in atheromas, 51 with CXCL10 also reducing Tregs in aortas. 52 Moreover, pDC depletion reduced vascular endothelium growth factor a potent angiogenic factor involved in vascular permeability, 53 the concentration of which increases in both serum and plaques during atherosclerosis. 39, 40 Despite the cytokine-mediated effects of pDCs, through the release of IFN-α, having been implicated in a pathogenic T-cell response in human atherosclerotic plaques, 26 IFN-α was below the level of detection in both aortic tissue and serum samples in our apoE −/− mice irrespective of pDC depletion. This suggests that large increases in IFN-α production are not responsible for the pDC-mediated atherogenic effect in our experimental settings, although it is possible there are minor localized increases in expression, which the immunoassay could not detect.
In conclusion, our results identify a critical role for pDCs in experimental atherosclerosis. These cells show significant plasticity with the capacity to produce high levels of cytokines/chemokines on one hand and orchestrate adaptive immune response on the other. One limitation of antibody depletion studies is that the bone marrow stromal antigen Ag is expressed on pDCs and plasma cells in naive mice but is induced on other cell types after stimulation with IFN-I or IFN-γ. 5 Therefore, pDC-depleting Abs could affect additional cell types (other than leukocytes) during chronic inflammation, thus confounding the interpretation of these studies. Alternative approaches are therefore needed to validate the role of pDCs in atherosclerosis.
The antigen presentation capacity may be an important cellular function of aortic pDCs in the pathology and merit further investigation; however, discriminating the MHC-II− dependent antigen presenting functions of pDCs from cytokine-mediated effects is not possible during pDC depletion. Recently, attempts have been made to selectively inhibit the MHC-II-dependent effects of pDCs while leaving other cellular functions, such as cytokine secretion, intact. 18 The outcome of that study was to confirm the importance of MHC-II−mediated antigen presentation in the tolerogenic functions of pDCs in an animal model of experimental autoimmune encephalomyelitis. 18 The use of such a model could be applied in the context of mouse models of atherosclerosis to evaluate the functional outcome of pDC antigen presentation. Determining which plaque-derived antigens stimulate pDCs and the functional consequences of antigen presenting pDCs will be critical to allow development of selective and appropriate immunotherapy targeting pDCs in atherosclerosis.
